Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) is looking to sell its Bausch & Lomb division’s surgical product assets to Carl Zeiss Meditec (ETR:AFX), according to a Bloomberg report. The surgical eye assets could be worth approximately $2 billion, according to the report, with a possible agreement still weeks away. No final decisions have been made, and other interested […]
Optical/Ophthalmic
Glaucoma laser developer Belkin Laser raises $5m
Ophthalmological device developer Belkin Laser has closed a $5.3 million round of financing, according to a Globes Israel report. The funding round was comprised of $2.5 million from Zico Holdings and Rimonci Capital and $2.8 million (EU €2.5 million) in an EU grant as part of the GLAUrious Program, which was initiated by Belkin Laser […]
Lamellar Biomedical launches dry-eye trial
Lamellar Biomedical said today that the 1st patients were enrolled in its trial evaluating Lamelleye for the treatment of moderate to severe dry-eye disease. Lamelleye uses the Scotland-based company’s Lamellasome technology to mimic the actions of serous lamellar bodies and regulate interfaces between tissues and external environments. Get the full story at our sister site, […]
UPDATE: Potential Alcon sale worries Novartis investors
Updated to include new details of Novartis’ M&A strategy. Novartis (NYSE:NVS) CEO Joe Jimenez’s consideration of the sale of the Alcon subsidiary has investors worried that the influx of cash – Alcon’s surgical devices and contact lens business could fetch as much as $35 billion – will result in another misguided acquisition. The Swiss drugmaker […]
Presbia touts preliminary data from Microlens PMA trial
Presbia (NSDQ:LENS) this week reported preliminary data from a US pivotal clinical trial of its Flexivue Microlens, touting that over 80% of subjects had shown significant improvements in vision. The Ireland-based company said it is 27 months into the 3-year trial which it hopes will support US FDA Premarket Approval, and that so far, 100% of subjects […]
Glaukos touts economic savings in dual iStent study
Glaukos (NYSE:GKOS) today touted data from an economic analysis of elevated intraocular pressure treatments in open-angle glaucoma patients, which reported low cost associated with the use of its iStent devices. The economic analysis study aimed to analyze direct cost for 3 treatment options for treating patients with elevated IOP open-angle glaucoma, including selective laser trabeculoplasty, topical […]
China’s Peaceful Union buys ClearSight Medical parent Sharklet Technologies
Chinese equity medical device firm Peaceful Union has acquired intraocular lens developer ClearSight‘s parent company, Sharklet Technologies, for an undisclosed amount. ClearSight is developing the ClearSight next-generation presbyopia-correction IOL, which it claims will improve upon current multifocal and accommodating IOL technologies. The company said its ClearSight IOL has an extended depth of field through the […]
LensGen raises $7.3m
Intraocular lens developer LensGen raised $7.3 million in a new round of equity funding, according to an SEC filing posted this week. The Irvine, Calif.-based company develops the Juvene accommodating intraocular lens. The Juvene lens is designed to potentially permanently restore clear and continuous vision at all distances for patients with cataracts and presbyopia, LensGen […]
Oxford robotic surgery, synthetic retina advances could help visually impaired
The University of Oxford has recently had some major advances for treating the visually impaired. Surgeons at the university recently performed the world’s first operation inside the eye using robotics and a student created what the university says is the first synthetic retina. Ophthalmology professor Robert MacLaren and Nuffield Medical fellow Dr. Thomas Edwards performed […]
Staar Surgical wins CE Mark for EVO+ Visian ICL, readies presbyopia study
Staar Surgical (NSDQ:STAA) said today it won CE Mark approval in the European Union for its Evo+ Visian ICL intraocular lens with Aspheric Optic technology, and reported that a presbyopia study of the device is underway. The Monrovia, Calif.-based company’s EVO+ Visian ICL is the company’s next-gen lens, designed to be surgically implanted and operate with the […]
Clearside Biomedical beats Q1 earnings consensus
Shares in Clearside Biomedical (NSDQ:CLSD) rose today after the biopharmaceutical company met expectations on Wall Street with its 1st quarter results. The Alpharetta, Ga.-based company posted a net loss of -$10.4 million, or -41¢ per share, on sales of $5,000 for the 3 months ended March 31, for bottom-line loss of -47.5 % compared with […]